Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting.

IF 2.5 Q3 ONCOLOGY Journal of Cancer Prevention Pub Date : 2021-03-30 DOI:10.15430/JCP.2021.26.1.71
Mark Steven Miller, Peter J Allen, Powel H Brown, Andrew T Chan, Margie L Clapper, Roderick H Dashwood, Shadmehr Demehri, Mary L Disis, Raymond N DuBois, Robert J Glynn, Thomas W Kensler, Seema A Khan, Bryon D Johnson, Karen T Liby, Steven M Lipkin, Susan R Mallery, Emmanuelle J Meuillet, Richard B S Roden, Robert E Schoen, Zelton D Sharp, Haval Shirwan, Jill M Siegfried, Chinthalapally V Rao, Ming You, Eduardo Vilar, Eva Szabo, Altaf Mohammed
{"title":"Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting.","authors":"Mark Steven Miller, Peter J Allen, Powel H Brown, Andrew T Chan, Margie L Clapper, Roderick H Dashwood, Shadmehr Demehri, Mary L Disis, Raymond N DuBois, Robert J Glynn, Thomas W Kensler, Seema A Khan, Bryon D Johnson, Karen T Liby, Steven M Lipkin, Susan R Mallery, Emmanuelle J Meuillet, Richard B S Roden, Robert E Schoen, Zelton D Sharp, Haval Shirwan, Jill M Siegfried, Chinthalapally V Rao, Ming You, Eduardo Vilar, Eva Szabo, Altaf Mohammed","doi":"10.15430/JCP.2021.26.1.71","DOIUrl":null,"url":null,"abstract":"<p><p>The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"26 1","pages":"71-82"},"PeriodicalIF":2.5000,"publicationDate":"2021-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020174/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15430/JCP.2021.26.1.71","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
会议报告:癌症预防制剂开发转化进展会议。
美国国立癌症研究所(NCI)癌症预防部和美国国立卫生研究院疾病预防办公室于 2020 年 8 月 27-28 日共同主办了癌症预防制剂开发转化进展会议。本次会议的目的是促进基础研究和临床研究领域领先的癌症预防研究人员之间的思想交流并激发新的合作互动;重点介绍免疫预防和化学预防领域的新趋势和新兴趋势以及临床试验的新信息;向校外研究界介绍国家癌症研究所可提供的大量资源,以促进预防制剂的开发和快速转化为临床试验。会议包括两场全体会谈和五场分会,涵盖范围从化疗/免疫预防剂的临床前研究到正在进行的癌症预防临床试验。此外,会议还举行了两场国家癌症研究所信息通报会,介绍了临床前制剂开发的合同资源和癌症预防临床试验网络的合作补助金。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
4.00%
发文量
32
期刊最新文献
Anticancer Activity of Phytochemicals of the Papaya Plant Assessed: A Narrative Review. Kaempferol Synergistically Enhances Cisplatin-induced Apoptosis and Cell Cycle Arrest in Colon Cancer Cells. Recommendations for Healthy Lifestyle for Cancer Prevention and Healthy Aging. Elevated N1-Acetylspermidine Levels in Doxorubicin-treated MCF-7 Cancer Cells: Histone Deacetylase 10 Inhibition with an N1-Acetylspermidine Mimetic. Ribosomal Protein L9 Maintains Stemness of Colorectal Cancer via an ID-1 Dependent Mechanism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1